Fig 1: IRF3, TRIF, and TRAM siRNA reduced COX-2 and mPGES-1 in rIL-1ß-treated LPS-primed U373-CD14 cells.U373-CD14 cells were transfected with control siRNA or with siRNA targeting TRIF or IRF3 (A, C), or TRAM (B, D). Transfected cells were left untreated (solid bars), or were incubated with LPS at 1 ng/ml (shaded bars), with rIL-1ß at 100 ng/ml for 18 h (striped bars), or were primed for 1 h with LPS and incubated with rIL-1ß for additional 18 h (open bars). Cells were collected and COX-2 mRNA (A, B) and mPGES-1 mRNA (C, D) expressions were assayed by qPCR. The data are shown as fold increase over control PCR with primers specific to ß-actin, run in the same samples. PCR was performed using triplicate wells and the data are shown as mean fold increase ± STDEV. This is representative of three experiments.